Table 2.
Association between CIN-1-month and overall survival in patients with metastatic colorectal cancer receiving TAS-102
| Sample or stratum | HR (95 % CI)a | P-value |
|---|---|---|
| Overall | 0.22 (0.12–0.38) | < 0.0001 |
| Strata | ||
| Men | 0.15 (0.06–0.33) | < 0.0001 |
| Women | 0.31 (0.13–0.67) | 0.0023 |
| Rectal | 0.36 (0.15–0.78) | 0.0092 |
| Colon | 0.15 (0.06–0.34) | < 0.0001 |
| RAS-mutant | 0.32 (0.15–0.64) | 0.001 |
| RAS-wild type | 0.14 (0.05–0.35) | < 0.0001 |
| Older adults (age > 65 years) | 0.19 (0.09–0.40) | < 0.0001 |
| Younger adults (age ≤ 65 years) | 0.21 (0.07–0.52) | 0.0003 |
| Higher Baseline CEA (> 55 ng/ml) | 0.26 (0.11–0.56) | 0.0004 |
| Lower Baseline CEA (≤ 55 ng/ml) | 0.18 (0.07–0.42) | < 0.0001 |
| Higher Baseline Neutrophil Count (> 4300/mm3) | 0.25 (0.08–0.57) | 0.0005 |
| Lower Baseline Neutrophil Count (≤ 4300/mm3) | 0.27 (0.11–0.65) | 0.0035 |
| Absolute Neutrophil cutoff at 1-month | ||
| CIN-1-month (< 1000/mm3) | 0.34 (0.16–0.66) | 0.0008 |
| CIN-1-month (< 1500/mm3) | 0.22 (0.12–0.38) | < 0.0001 |
| CIN-1-month (< 2000/mm3) | 0.28 (0.17–0.47) | < 0.0001 |
| CIN-1-month (< 2500/mm3) | 0.25 (0.16–0.42) | < 0.0001 |
| CIN-1-month (< 3000/mm3) | 0.26 (0.16–0.43) | < 0.0001 |
aHR for overall survival was calculated through Cox proportional hazards models